Education
About Us
Working with TipRanks
Follow Us
Pyxis Oncology (PYXS)
NASDAQ:PYXS
PYXS Stock Chart & Stats
$1.49
-$0.10(-5.75%)
At close: 4:00 PM EST
$1.49
-$0.10(-5.75%)
Day’s Range― - ―
52-Week Range$0.83 - $5.55
Previous CloseN/A
Volume258.73K
Average Volume (3M)757.02K
Market Cap
$84.06M
Enterprise Value$92.74M
Total Cash (Recent Filing)$77.73M
Total Debt (Recent Filing)$19.07M
Price to Earnings (P/E)―
Beta1.11
Next Earnings
Mar 25, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding62,264,214
10 Day Avg. Volume789,983
30 Day Avg. Volume757,017
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.76
Price to Sales (P/S)5.65
P/FCF Ratio-1.57
Enterprise Value/Market Cap1.10
Enterprise Value/Revenue32.89
Enterprise Value/Gross Profit32.89
Enterprise Value/Ebitda-1.14
Forecast
1Y Price Target
$6.50Price Target Upside336.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.21
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Business DevelopmentRenewed industry appetite for antibody-drug conjugates increases the likelihood of partnership or acquisition discussions for Pyxis and the MICVO asset.
Clinical EfficacyConfirmed objective response rates in later-line monotherapy and combination cohorts exceeded expectations, reinforcing MICVO's potential clinical differentiation versus peer programs.
Enrollment And Data CatalystsActivation of specialized cancer study sites and an expected increase in patient enrollment during 2026 should broaden the dataset ahead of key clinical updates, making upcoming readouts higher-impact.
Bears Say
Clinical Trial ExecutionSmall cohort sizes and a gradual pace of enrollment have produced a complex, potentially ambiguous readout that may undermine investor confidence and delay a clear assessment of efficacy.
Financial ResourcesDepleting cash reserves coupled with ambiguous clinical data increase financial runway risk and could pressure the stock if additional funding becomes necessary.
Safety And TolerabilityElevated treatment discontinuation and occurrences of severe treatment-related adverse events raise tolerability concerns that could limit MICVO's competitive positioning and complicate regulatory assessment.
Pyxis Oncology News
PYXS FAQ
What was Pyxis Oncology’s price range in the past 12 months?
Pyxis Oncology lowest stock price was $0.83 and its highest was $5.55 in the past 12 months.
What is Pyxis Oncology’s market cap?
Pyxis Oncology’s market cap is $84.06M.
When is Pyxis Oncology’s upcoming earnings report date?
Pyxis Oncology’s upcoming earnings report date is Mar 25, 2026 which is in 18 days.
How were Pyxis Oncology’s earnings last quarter?
Pyxis Oncology released its earnings results on Nov 03, 2025. The company reported -$0.35 earnings per share for the quarter, missing the consensus estimate of -$0.334 by -$0.016.
Is Pyxis Oncology overvalued?
According to Wall Street analysts Pyxis Oncology’s price is currently Undervalued.
Does Pyxis Oncology pay dividends?
Pyxis Oncology does not currently pay dividends.
What is Pyxis Oncology’s EPS estimate?
Pyxis Oncology’s EPS estimate is -0.34.
How many shares outstanding does Pyxis Oncology have?
Pyxis Oncology has 62,264,214 shares outstanding.
What happened to Pyxis Oncology’s price movement after its last earnings report?
Pyxis Oncology reported an EPS of -$0.35 in its last earnings report, missing expectations of -$0.334. Following the earnings report the stock price went up 7.022%.
Which hedge fund is a major shareholder of Pyxis Oncology?
Currently, no hedge funds are holding shares in PYXS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pyxis Oncology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.50 (336.24% Upside)
$6.50 (336.24% Upside)
Hedge Fund Trend
Decreased
By 1.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
148.23%
12-Months-Change
Fundamentals
Return on Equity
-87.28%
Trailing 12-Months
Asset Growth
-45.93%
Trailing 12-Months
Company Description
Pyxis Oncology
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
PYXS Stock 12 Month Forecast
Average Price Target
$6.50
▲(336.24% Upside)
Technical Analysis
Nkarta
―
Greenwich LifeSciences
―
Elicio Therapeutics
―
Biomea Fusion
―
Nuvectis Pharma
―
Ownership Overview
10.26%
Insiders
4.03% Mutual Funds
21.08% Other Institutional Investors
60.54% Public Companies and Individual Investors